Symbolbild · KI-generiert
CytomX Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
CytomX Therapeutics develops Probody therapeutics, a class of masked antibodies that are selectively activated within tumour tissue to reduce side effects. The company pursues both proprietary oncology programmes and partnerships with larger pharmaceutical companies.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| CytomX Therapeutics, Inc. | CTMX | NASDAQ | 675 Mio. USD |
| Nuvectis Pharma, Inc. | NVCT | NASDAQ | 678 Mio. USD |
| CeriBell, Inc. | CBLL | NASDAQ | 671 Mio. USD |
| Rigel Pharmaceuticals, Inc. | RIGL | NASDAQ | 681 Mio. USD |
| Climb Bio, Inc. | CLYM | NASDAQ | 681 Mio. USD |
| Enghouse Systems Limited | ENGH | TSX | 663 Mio. USD |
| Knight Therapeutics Inc. | GUD | TSX | 689 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.